Endotis reports the successful completion of Phase I clinical trials of neutralizable anticoagulant EP217609 and antidote avidin

03-May-2010 - France

Efficient inline analysis for liquids and solids

Revolutionize your production: real-time Raman analysis for maximum efficiency

Freeze Drying with the Refrigerant of the Future

Endotis Pharma announced that the neutralizable anticoagulant EP217609 and its specific antidote avidin have successfully completed their respective first-in-man Phase I clinical trials.

EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized with a specific antidote (avidin - an egg-derived protein). It has a dual mechanism of action which combines indirect factor Xa inhibition and direct thrombin inhibition. EP217609 is the neutralizable version of EP42675, which has already successfully completed a Phase I program in 108 healthy subjects.

EP217609 was well tolerated in 24 healthy subjects exposed to single, ascending doses. As expected, administration of the EP217609 anticoagulant resulted in dose-dependent increases in standard and specific coagulation tests, whereas a decrease in thrombin generation was observed. EP217609 ‘s pharmacodynamic and pharmacokinetic profiles were predictable, with low inter-subject variability. In a separate trial, avidin was well tolerated in 24 healthy subjects exposed to single, ascending doses. There was no evidence of hypersensitivity reactions.

https://www.bionity.com/en/news/117059/endotis-reports-the-successful-completion-of-phase-i-clinical-trials-of-neutralizable-anticoagulant-ep217609-and-antidote-avidin.html